Improving the availability of artesunate for treatment of severe malaria

Medical Journal of Australia

Volumn 184, Issue 1, 2006, Pages 3-4

  Anstey, Nicholas M ^a   Price, Ric N ^a   White, Nicholas J ^b  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; ARTEMISININ DERIVATIVE; ARTESUNATE; QUININE;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG SAFETY; EDITORIAL; GEOGRAPHIC DISTRIBUTION; GOOD MANUFACTURING PRACTICE; HEADACHE; HEALTH CARE AVAILABILITY; HEALTH SERVICE; HUMAN; HYPOGLYCEMIA; LICENSING; MALARIA; MORTALITY; PATIENT SATISFACTION; QUALITY OF LIFE; RISK ASSESSMENT; TINNITUS; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 31444438297     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2006.tb00084.x     Document Type: Editorial

References (13)

1. Artemether-Quinine Meta-analysis Study Group. A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Trans R Soc Trop Med Hyg 2001; 95: 637-650.
2. Murphy SA, Mberu E, Muhia D, et al. The disposition of intramuscular artemether in children with cerebral malaria; a preliminary study. Trans R Soc Trop Med Hyg 1997; 91: 331-334.
3. Hien TT, Davis TM, Chuong LV, et al. Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob Agents Chemother 2004; 48: 4234-4239.
4. Davis TM, Phuong HL, Ilett KF, et al. Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria. Antimicrob Agents Chemother 2001; 45: 181-186.
5. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) Group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366: 717-725.
6. Snow RW, Guerra CA, Noor AM, et al. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005; 434: 214-217.
7. Davis TM, Karunajeewa HA, Ilett KF Artemisinin-based combination therapies for uncomplicated malaria. Med J Aust 2005; 182: 181-185.
8. World Health Organization global antimalarial drug policy database, 2005. Available at: http://www.who.int/malaria/amdp/amdp_searo.htm and http://www.who.int/malaria/amdp/amdp_wpro.htm (accessed Nov 2005).
9. Magill A, Panosian C. Making antimalarial agents available in the United States. N Engl J Med 2005; 353: 335-337.
10. World Health Organization. Guidelines for the treatment of malaria. Geneva: WHO, 2006. In press.
11. Bruneel F, Hocqueloux L, Alberti C, et al. The clinical spectrum of severe imported falciparum malaria in the intensive care unit: report of 188 cases in adults. Am J Respir Crit Care Med 2003; 167: 684-689.
12. Australian Government. Therapeutic Goods Act 1989. Available at: http://www.comlaw.gov.au/ComLaw/Legislation/ActCompilation1.nsf/ framelodgmentattachments/8D8974B9D6A524C6CA256FBF001233C8 (accessed Nov 2005).
13. Therapeutic Goods Administration. Special Access Scheme: access to unapproved therapeutic goods. Canberra: Department of Health and Ageing, 2001.